Featuring a discussion and Q&A with Carlo Rizzuto, operating principal of Versant Ventures, a leading healthcare investment firm investing across the sector at all stages, with an emphasis on early-stage investment in therapeutics. In this video Carlo discusses Versant Ventures’ new $300 million fund for investing in bioscience, as well as other recent exciting developments and trends in venture capital and healthcare investing.